Michael Sailor

Cend Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapies for solid tumor cancers. Its offers CendR Platform, which provides a targeted tissue penetration capability to specifically enhance drug delivery to tumors. Its lead compound CEND-1 seeks out tumors and activates the CendR transport pathway. The company was founded by Erkki Ruoslahti in 2016 and is headquartered in San Diego, CA.

Cend Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapies for solid tumor cancers. Its offers CendR Platform, which provides a targeted tissue penetration capability to specifically enhance drug delivery to tumors. Its lead compound CEND-1 seeks out tumors and activates the CendR transport pathway. The company was founded by Erkki Ruoslahti in 2016 and is headquartered in San Diego, CA.

Cend Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapies for solid tumor cancers. Its offers CendR Platform, which provides a targeted tissue penetration capability to specifically enhance drug delivery to tumors. Its lead compound CEND-1 seeks out tumors and activates the CendR transport pathway. The company was founded by Erkki Ruoslahti in 2016 and is headquartered in San Diego, CA.

Impilo Therapeutics, Inc. engages in the development of platform for delivering nucleic acid-based medicines to solid tumor cancers. The company was founded by Sangeeta N. Bhatia, Frank J. Slack, and Michael Sailor and is headquartered in San Diego, CA.

Impilo Therapeutics, Inc. engages in the development of platform for delivering nucleic acid-based medicines to solid tumor cancers. The company was founded by Sangeeta N. Bhatia, Frank J. Slack, and Michael Sailor and is headquartered in San Diego, CA.